Asynt's Felxible Gas Pressure Reactors
Asynt has announced a range of compact gas pressure reactors designed to be heated and stirred using standard hotplate stirrers with the unique DrySyn adapter that ensures excellent heat transfer.
The base vessels are available from 50 mL to 500 mL and are rated up to 200 Barr and 200 ºC enabling reactions including hydrogenation, carbonylation and carboxylation at elevated temperatures and pressures to be routinely performed.
With the added flexibility of standard and custom DrySyn inserts, Asynt gas pressure reactors provide chemists with a platform to undertake a single reaction from 100s of microlitres, by itself or in parallel, up to a single reaction to the volume of the vessel.
All vessels can be provided with a bursting disc, pressure gauge, pressure relief valve, PT100 temperature probe, thermowell for PT100, cooling coil, magnetic overhead stirrer with standard impeller (316 stainless steel), high pressure burette assembly and a range of glass or PTFE inserts and liners as well as PEEK internals if necessary.
For further information or to discuss your application please contact Asynt on +44 1638 781 709 or [email protected].
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...